Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.

[1]  M. Jayaram,et al.  Risperidone versus placebo for schizophrenia. , 2016, The Cochrane database of systematic reviews.

[2]  P. Rompré,et al.  Clinimetric Evaluation of the Simpson-Angus Scale in Older Adults With Schizophrenia , 2014, Journal of clinical psychopharmacology.

[3]  T. Kishimoto,et al.  Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. , 2013, Journal of child and adolescent psychopharmacology.

[4]  M. DelBello,et al.  Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. , 2013, Journal of child and adolescent psychopharmacology.

[5]  M. DelBello,et al.  Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. , 2013, Journal of child and adolescent psychopharmacology.

[6]  M. DelBello,et al.  Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. , 2013, Journal of child and adolescent psychopharmacology.

[7]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[8]  C. Correll,et al.  Aripiprazole for the treatment of pediatric bipolar I disorder: a 30‐week, randomized, placebo‐controlled study , 2013, Bipolar disorders.

[9]  M. DelBello,et al.  Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. , 2013, The Journal of clinical psychiatry.

[10]  R. Findling,et al.  Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. , 2012, Journal of child and adolescent psychopharmacology.

[11]  P. Russell,et al.  Atypical antipsychotics for psychosis in adolescents. , 2012, The Cochrane database of systematic reviews.

[12]  S. Patten,et al.  Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children , 2011, Drug safety.

[13]  Carmen Moreno,et al.  Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons , 2011, European Neuropsychopharmacology.

[14]  J. Kane.  Addressing side effects from antipsychotic treatment in schizophrenia. , 2011, The Journal of clinical psychiatry.

[15]  R. Kahn,et al.  Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. , 2010, Schizophrenia bulletin.

[16]  J. Bishop,et al.  Anticholinergic Use in Children and Adolescents After Initiation of Antipsychotic Therapy , 2010, The Annals of pharmacotherapy.

[17]  M. DelBello,et al.  Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. , 2010, Bipolar disorders.

[18]  H. Swadi,et al.  A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents , 2010, International clinical psychopharmacology.

[19]  M. Copenhaver,et al.  A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. , 2009, Journal of child and adolescent psychopharmacology.

[20]  R. Findling,et al.  Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder , 2009, Pediatrics.

[21]  M. DelBello,et al.  Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. , 2009, Bipolar disorders.

[22]  R. Mcquade,et al.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[23]  Barbara Napolitano,et al.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.

[24]  R. Kauffman,et al.  An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. , 2009, Journal of child and adolescent psychopharmacology.

[25]  R. Dittmann,et al.  The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. , 2009, The Journal of clinical psychiatry.

[26]  C. Arango,et al.  Olanzapine compared to quetiapine in adolescents with a first psychotic episode , 2009, European Child & Adolescent Psychiatry.

[27]  J. Singer,et al.  Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. , 2009, The British journal of psychiatry : the journal of mental science.

[28]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[29]  R. Findling,et al.  A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. , 2008, The American journal of psychiatry.

[30]  Ann E. Maloney,et al.  Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. , 2008, The American journal of psychiatry.

[31]  M. Versavel,et al.  Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. , 2008, Journal of child and adolescent psychopharmacology.

[32]  Jeffrey A. Lieberman,et al.  Extrapyramidal side-effects of antipsychotics in a randomised trial , 2008, British Journal of Psychiatry.

[33]  J. Castro-Fornieles,et al.  Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. , 2008, Journal of child and adolescent psychopharmacology.

[34]  S. Factor,et al.  Failure of recognition of drug‐induced parkinsonism in the elderly , 2008, Movement disorders : official journal of the Movement Disorder Society.

[35]  C. Correll,et al.  One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. , 2007, Journal of child and adolescent psychopharmacology.

[36]  M. Tohen,et al.  Olanzapine versus placebo in the treatment of adolescents with bipolar mania. , 2007, The American journal of psychiatry.

[37]  J. Balázs,et al.  Methylphenidate-induced orofacial and extremity dyskinesia. , 2007, Journal of child and adolescent psychopharmacology.

[38]  P. Weiden.  EPS Profiles: The Atypical Antipsychotics: Are Not All the Same , 2007, Journal of psychiatric practice.

[39]  Abraham Weizman,et al.  An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. , 2006, Journal of child and adolescent psychopharmacology.

[40]  C. McDougle,et al.  Acute and long-term safety and tolerability of risperidone in children with autism. , 2005, Journal of child and adolescent psychopharmacology.

[41]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[42]  R. Dardennes,et al.  Olanzapine for schizophrenia. , 2005, The Cochrane database of systematic reviews.

[43]  M. Holi,et al.  Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population , 2005, BMC neurology.

[44]  S. Lankappa,et al.  Quetiapine for schizophrenia. , 2004, The Cochrane database of systematic reviews.

[45]  S. Potkin,et al.  Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. , 2003, Archives of general psychiatry.

[46]  S. Kasper,et al.  Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol , 2002, Psychopharmacology.

[47]  R. Lewis.  Typical and Atypical Antipsychotics in Adolescent Schizophrenia: Efficacy, Tolerability, and Differential Sensitivity to Extrapyramidal Symptoms , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[48]  T. Ishikawa,et al.  Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[50]  J. Kane,et al.  Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.

[51]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[52]  C. Correll.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. , 2008, Journal of the American Academy of Child and Adolescent Psychiatry.

[53]  F. Sallee,et al.  A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. , 2008, The Journal of clinical psychiatry.

[54]  A. Malhotra,et al.  Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. , 2006, Child and adolescent psychiatric clinics of North America.

[55]  M. Sorter,et al.  Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. , 2003, Journal of child and adolescent psychopharmacology.

[56]  Abraham Weizman,et al.  Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. , 2003, Journal of child and adolescent psychopharmacology.

[57]  M. Tohen,et al.  A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. , 2001, Journal of child and adolescent psychopharmacology.